Physician profile
Michael J Blanco
NPI 1508284456
$5,757.63
in general payments reported to CMS, 2019-2025
38 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $76.61 · 2021: $175 · 2022: $1,305 · 2023: $1,738 · 2024: $899 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.99 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,589.04 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.49 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $445.13 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $368.88 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $245.05 | 2021-2025 | |
| Ardelyx, INC. | $203.53 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $181.31 | 2022-2025 | |
| Braintree Laboratories, INC. | $180.08 | 2022-2024 | Suflave, Sutab |
| Celgene Corporation | $171.40 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $171.07 | 2022-2025 | Rebyota |
| Intuitive Surgical, INC. | $154.56 | 2022 | |
| Qol Medical, LLC | $149.45 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $120.13 | 2024-2025 | Resmetirom, Rezdiffra |
| Regeneron Pharmaceuticals, INC. | $99.75 | 2024 | Dupixent |
| Medline Industries LP | $96.01 | 2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.